Castle Biosciences says ACG 2026 data show TissueCypher flags Barrett’s progression risk beyond biopsy findings
CSTL•Castle Biosciences said data from two case reports and a multicenter study show TissueCypher flagged higher Barrett’s esophagus progression risk than biopsy findings suggested, prompting earlier escalation of care.
1. Data to be presented
Castle Biosciences announced new TissueCypher data in Barrett’s esophagus scheduled for presentation at the ACG 2026 meeting in Nashville. The company said clinicians changed surveillance or treatment plans in most tested patients, and the test helped resolve conflicting pathology assessments.
